Home›Trial›NCT05131100
NCT05131100Completed

Korean Regulatory Post Marketing Surveillance for Somavert

Study Summary

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Conditions
Acromegaly
Interventions / Drugs
Somavert
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
C52/100
Study Details
Enrollment11 participants
Primary Completion2025-11-10
Lead SponsorPfizer
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Primary completion: 2025-11-10
Enrolled: 11 participants
Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →
Other Trials from Pfizer Inc
NCT05805826To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons…(PHASE1/PHASE2)NCT07215078Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure a…(PHASE1)NCT07363694A Study to Learn About the Study Medicine Called PF-07275315 in People With Mode…(PHASE2/PHASE3)NCT05571839A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors(PHASE1)NCT07222800Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in…(PHASE3)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence